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Edited by David LambethAbstract We have studied the production of reactive oxygen
species (ROS) in transmitochondrial cells, harboring homoplas-
mic levels of the T14487C mtDNA mutation in the ND6 gene
of mitochondrial DNA (mtDNA). Previous work has shown that
this mutation causes complex I deﬁciency. Here, we show that
this mutation causes an overproduction of ROS leading to an
increase in the oxidation of lipids and mtDNA without modiﬁca-
tion of antioxidant enzyme activities. We suggest that mutations
in mtDNA aﬀecting complex I activity may result in oxidative
cellular damage, and reinforce the possible role of ROS-
mediated mechanisms participating in some mtDNA-related
disorders.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Mitochondrial DNA (mtDNA) point mutations have been
associated with a wide range of clinical presentations ranging
from pure myopathies to multisystem disorders [1]. Despite
the great eﬀorts made in recent years to understand the geno-
type–phenotype relationship in mitochondrial disorders, the
precise mechanisms that result in a particular clinical pheno-
type remain far from being understood. Although it is believed
that impairment of ATP synthesis plays a key role in the clin-
ical presentation of mitochondrial disorders, there is growing
evidence that other biochemical pathways may be involved.
In recent years, a substantial amount of work has suggested
that reactive oxygen species (ROS)-mediated damage plays
an important role in the pathogenesis of cell damage caused
by mtDNA mutations [2]. However, very few systematic stud-
ies in controlled experimental models have been performed to
assess this hypothesis.
We present biochemical data on a cell model of the T14487C
mutation in the ND6 gene of mtDNA. This mutation has been
recently identiﬁed independently by three groups inpatientswith*Corresponding author. Fax: +34 934894040.
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doi:10.1016/j.febslet.2005.11.034aLeigh-like orbilateral striatal necrosis syndrome [3–5].Herewe
report that transmitochondrial cybrids harboring homoplasmic
levels of the mutation showed an increase in ROS production
which results in lipid and mtDNA oxidative damage. Interest-
ingly, in this model, the over-production of ROS did not result
in an increase in antioxidant enzyme defenses.
These results suggest that mutations in complex I (nuclear or
mtDNA) genes may lead to a signiﬁcant increase in ROS pro-
duction and a subsequent increase in oxidative damage in cell
lipids and mtDNA.2. Materials and methods
Biochemical studies were carried out on a transmitochondrial cell
line harboring homoplasmic levels of the T14487C mutation (ND6
100%), and wild-type control cybrids (WT) whose biochemical pheno-
type has been previously characterized [3].
2.1. ROS production
Cells (2.5 · 105) were collected by trypsinization and resuspended in
PBS. Twenty-four microliters of the 1.25 mM cell-permeate probe
2 0,7 0-dichloroﬂuorescein diacetate (DCFH-DA) solution was added
to each cell suspension and incubated for 15, 30, and 45 min at
37 C. Fluorescence was analyzed in a ﬂuorimeter (SFM 25, Kontron
Instruments. 488 nm excitation and 525 nm emission). Results were
referred to a standard curve of dichloroﬂuorescein (DCF). DCF ﬂuo-
rescence has been previously described that is linear in the nanomolar
range with hydrogen peroxide [6], thus the results can be expressed as
fmol of hydrogen peroxide.
2.2. Antioxidant enzyme activities
Cells were grown to conﬂuence, and 60–70 million cells were har-
vested for each sample with trypsin–EDTA, washed twice, suspended
in PBS and frozen at 80 C until analysis. Samples were homogenized
in PBS, sonicated for 5 min and centrifuged to isolate the supernatant.
Total superoxide dismutase (SOD) activity was determined according
to McCord and Fridovich [7], measuring the inhibition of the
cytochrome c reduction by superoxide radical. Mn-SOD activity was
measured in the presence of 10 mM KCN. Glutathion peroxidase
(GSH-Px) was measured using the method of Lawrence and Burk [8]
in which GSH-Px activity is coupled to the oxidation of NADPH by
glutathione reductase monitored at 340 nm. Catalase (CAT) assay
was performed spectrophotometrically according to Aebis method
by monitoring the degradation of H2O2 at 240 nm [9].
2.3. Lipid peroxidation
Lipid peroxidation was assessed by measuring the levels of the mal-
ondialdehyde–thiobarbituric acid (MDA–TBA) adduct in cell extracts
as previously described [10]. Brieﬂy, cells (6.0 · 106) were collected andblished by Elsevier B.V. All rights reserved.
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toluene (3 mM) was added to avoid de novo peroxidation. Samples
were incubated in the presence TBA (42 mM). After incubation,
0.1 ml of 70% perchloric acid was added and the sample was centri-
fuged. Twenty microliters of the supernatant was injected into the
HPLC system (Alliance 2695 system, Waters Corporation, USA, Sym-
metry C18 5 lm column). The mobile phase was composed of 60%
potassium phosphate 50 mM, pH 6.8, and 40% methanol. The eluate
was monitored ﬂuorometrically, and the adduct MDA–TBA quanti-
ﬁed based on comparison with a calibration curve of 1,1,3,3-tetraeth-
oxypropane.
2.4. Measurement of mtDNA oxidation (QPCR)
The basis of the QPCR assay is that lesions present in the DNA block
the progression of any thermostable polymerase on the template, result-
ing in the decrease of DNA ampliﬁcation in the damaged template
[11,12]. Brieﬂy, total DNA was extracted using QIamp DNA Mini Kit
(QiAgen, GmbH, Germany) and quantitated spectrophotometrically.
Aliquots of DNA (50–100 ng) were then subjected to QPCR. Two frag-
ments of mtDNA were ampliﬁed (mtDNA primers for fragment of
8.9 kb; sense 5 0-TTTCATCATGCGGAGATGTTGGATGG-3 0 and
antisense 5 0-TCTAAGCCTCCTTATTCGAGCCGA-3 0; fragment of
207 bp; sense 5 0-ACTTCCTACCACTCACCCTA-3 0 and antisense 5 0-
TGATAGGTGGCACGGACAAT-30). QPCRs were performed with
the GeneAmp XL PCR kit (Perkin–Elmer) as previously described
[12]. An aliquot of each PCR product was resolved on a 0.8% agarose
gel and electrophoresed in TBE at 90 V for 45 min. The gels were stained
with EtBr and the density of the bandswere obtained and processedwith
the Quantity One software (Biorad, Hercules, CA).
2.5. Protein oxidation
Western blot analysis of carbonyl groups content in proteins from
cell extracts was used to assess the levels of protein oxidation [13].
Brieﬂy, cells were homogenized and proteins were derivatized with
2,4-dinitrophenylhydrazine and separated (10 lg protein per lane) by
SDS–PAGE (12%). After electrophoresis, proteins were transferred
to an Immobilon-P PVDF membrane (Millipore Corporation, Bed-
ford, MA). Primary antibody was anti-2,4-dinitrophenol (DNP) devel-
oped in rabbit (DAKO A/S Denmark) at a 1:100000 dilution. A goat
anti-rabbit immunoglobulin G conjugated with horseradish peroxidase
(DAKO A/S Denmark) (1:5000) was used to estimate the relative
amount of protein oxidation, using ECL + plus Western blotting
detection system (Amersham Biosciences, England). Densitometric
analyses of the immunoblots were performed and intensities normal-
ized by protein content (Coomassie blue staining).
2.6. Protein determination
Protein content was determined using the Coomassie plus protein as-
say reagent (Pierce, Rockford, IL). Antioxidant enzyme activities and
MDA were expressed per mg of protein.3. Results
3.1. ROS production
ROS production was studied in T14487C/ND6 mutant cy-
brids using the cell-permeate probe DCFH-DA. ROS produc-
tion was studied in T14487C/ND6 mutant cybrids using the
cell-permeate probe DCFH-DA. DCFH reacts very fast with
endogenous reactive intermediates, including superoxide an-
ions, hydrogen peroxide and hydroxyl radicals in the moment
that the assay is performed. DCFH reacts very fast with endog-
enous reactive intermediates, including superoxide anions,
hydrogen peroxide and hydroxyl radicals in the moment that
the assay is performed. Fig. 1 shows thatROSproduction signif-
icantly increased in the transmitochondrial cell line harboring
homoplasmic levels of the mutation (P < 0.001). A 1.32-fold in-
crease in hydrogen peroxide ROS production was observed
when compared to controls (1.28 vs. 1.69 fmols H2O2 pro-
duced/min cell).3.2. Antioxidant enzyme activities
Fig. 2 shows the results of the antioxidant enzyme activities.
Panel A shows total SOD and mitochondrial SOD (Mn-SOD)
activities, panel B CAT activity and panel C total GSH-Px and
Se-GSH-Px form. There were no signiﬁcant diﬀerences in any
of the antioxidant enzymes analyzed (P > 0.05).3.3. Lipid, mtDNA and protein oxidation
In this cellmodel, oxidative damage to lipid,mtDNAandpro-
tein was studied. Fig. 3 shows a signiﬁcant increase in both lipid
peroxidation (assessed by the MDA–TBA assay, panel A; con-
trol cell line 0.29 ± 0.071 vs.mutant cell line 0.39 ± 0.13 nmolM-
DA/mg prot), and mtDNA oxidation (measured by QPCR,
panel B; control cell line 100 ± 19.1 vs. mutant cell line 74.4 ±
24.6, measured as relative ampliﬁcation%). However protein
oxidation, estimated as the levels of carbonyl group contents
in proteins of cell homogenates, was not signiﬁcantly increased
in T14487C/ND6 mutant cybrids (panel C; control cell line
100 ± 22 vs. mutant cell line 127 ± 91, measured as protein oxi-
dation increase%).4. Discussion
Using a transmitochondrial cell line harboring homoplasmic
levels of the T14487C mtDNA mutation, we aimed to study
the production of ROS as well as the putative damage pro-
duced by these species on cell biomolecules. We previously
demonstrated [3] that this mutation causes isolated complex
I deﬁciency in muscle and a virtual abolition of oxygen con-
sumption in the same transmitochondrial cell line. The same
mutation has been identiﬁed by Ugalde et al. and Lebon
et al. in patients with Leigh-like syndrome [4,5] showing that
the mutation causes reduction of complex I activity in both pa-
tients ﬁbroblasts and cybrids [4]. Ugalde et al. [4] showed an
alteration in levels of fully assembly complex I (measured by
blue native electrophoresis) in the patients ﬁbroblasts and cy-
brids, suggesting that this mutation may impair complex I
assembly and mobility. Here, we show that the production
of hydrogen peroxide increases in the transmitochondrial cell
line harboring homoplasmic levels of the mutation (1.28 vs.
1.69 fmols H2O2 produced/min cell) This is not surprising, as
complex I is, with complex III, the major source of ROS in
cells [14,15]. Mutations in subunits of complex I or III may
lead to a similar situation. The rate of O2 formation by the
respiratory chain is controlled by mass action, and increases
when the electron ﬂow slows down [16]. Defectively assembled
complexes of the electronic respiratory chain may lead to this
situation.
A study performed in patients harboring mutations in nucle-
ar-encoded complex I subunits showed a signiﬁcant decrease in
the levels of intact complex I, indicating that complex I assem-
bly and/or stability is compromised [17]. Furthermore, in the
same study the authors suggest that mutations in complex I
can also aﬀect the stability of other respiratory chain com-
plexes; therefore, we cannot rule out the possibility that the
T14487C mutation aﬀects not only complex I, but also com-
plex III, increasing the production of ROS, as complexes I
and III are the main sources of ROS. This hypothesis has been
recently reinforced by the demonstration that complex I
assembly is dependent on the assembly of complex III [18].
Fig. 1. ROS production in wild type (WT) and mutant cybrid cells
lines. Mutant cells show a 1.3-fold increase when compared to the WT
cells. Results of three independent assays are depicted. All samples
were analysed in duplicates. Mean and standard deviation are
represented (\P < 0.001; Mann–Whitney test).
Fig. 2. Antioxidant enzyme activities. Panel A: Activities of total-SOD
and Mn-SOD. Panel B: CAT activity. Panel C: Activities of total
(GSH-Px) and selenium dependent glutathion peroxidase (SeGSH-Px).
No diﬀerences were observed in any of the activities of these enzymes
between mutated and WT cells (P > 0.05). All samples were analysed
in duplicates and results of six independent assays are depicted. Mean
and standard deviation are represented (Mann–Whitney test).
R. Gonzalo et al. / FEBS Letters 579 (2005) 6909–6913 6911Direct or indirect evidence of an increase in ROS production
due to mtDNA mutations has been extensively studied with
the use of electronic transport chain inhibitors [19], however
there are only a few works reporting ROS production associ-
ated with mutations in the mtDNA using the model of xenom-
itochondrial cybrids [20,21]. In one of these studies, Rana et al.
[21] showed an increase in hydrogen peroxide production in
transmitochondrial cybrids harboring a microdeletion in the
mitochondrial cytochrome b gene. This was the ﬁrst solid evi-
dence of increase in ROS production due to a mtDNA muta-
tion in a cybrid cell system and the authors suggested that the
neurodegeneration features observed in the patient could be re-
lated to the damage produced by ROS. More recently, it has
been shown that cybrids harboring Lebers disease-related
mtDNA mutations have an increase in ROS production
[20,22].
We showed in a study on cybrids harbouring mtDNA tRNA
mutations (A3243G, A8344G) [23], that an increase in antiox-
idant enzyme activities is produced in response to an overpro-
duction of ROS in MELAS and MERRF cybrids, preventing
oxidative damage. Oxidative damage results from an imbal-
ance between free radical generation and detoxiﬁcation by
antioxidant defences. Here, cybrid cells harboring the 14487/
ND6 mutation show overproduction of ROS leading to lipid
and mtDNA oxidative damage. This observation, suggests
that this damage could be produced by the failure of upregu-
late the activities of antioxidant enzymes. The reason why
ROS generated by complex I deﬁciency fail to induce upregu-
lation of antioxidant enzymes is not clear. A possible explana-
tion could be the speciﬁc site of production of ROS in the
electronic transport chain. Therefore, ROS generated only in
complex I (as in the 14487/ND6 mutation) are released to
the mitochondrial matrix, while ROS generated from com-
plexes I + III (as in the tRNA mutations) are released to both
mitochondrial matrix and intermembrane space [14,15].
Floreani et al. [24] showed in cybrids harbouring the 14484/
ND6 mutation, no variations in the activity of catalase and
GSH-Px. Moreover, Pitka¨nen et al. [25], using ﬁbroblast cul-
tures with complex I deﬁciency, demonstrated low levels of
MnSOD in cells with high ROS production, and Esposito
et al. [26], did not ﬁnd MnSOD increase in heart mitochondria
of Ant1-deﬁcient mice. Some hypotheses have been posed to
explain this phenomenon, postulating a diﬀerent tissue regula-tion in the expression of antioxidant enzymes [26], inﬂuence of
redox state of the cell in enzyme activation [25] or decrease in
antioxidant defenses due to mutations which produces high
levels of ROS [24]. Further studies are needed to clarify the
antioxidant enzymes regulation in these situations.
A pathogenic role of ROS in mitochondrial disorders has
been hypothesized, on the basis of the ability of mitochondria
to produce abnormally high levels of these toxic species when
the respiratory chain is impaired [26], and also because of the
ROS-related clinical phenotypes of some mitochondrial
encephalomyopathies [27]. Interestingly, in this study, the
Fig. 3. Oxidative damage to lipids, mtDNA and proteins. Panel A:
Lipid peroxidation assessed by the MDA–TBA assay. Mutated cells
show higher values of MDA than control cells (\P < 0.001, Mann–
Whitney test). Panel B: mtDNA oxidative damage. Mutated cells
show higher oxidative damage than control cells (\P < 0.05, Willcoxon
test). Upper panel depicts the diﬀerent ampliﬁcation eﬃciency of
mutated cell line vs. control cell line. Lower panel shows a represen-
tative experiment of a QPCR ampliﬁcation product of the 8.9 kb and
207 pb fragments. Panel C: Protein oxidative damage assessed by the
carbonyl assay. Mutant cells show no signiﬁcant increase in carbonyl
groups.
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increases in ROS production but also clear evidence of oxida-
tive damage to cell biomolecules, suggesting a possiblecontribution of oxidative stress to the pathogenesis of the
ND6 mutation.
These results indicate that mutations in mtDNA leading to
complex I deﬁciency may result in an increase in ROS. There-
fore, in vivo studies are needed to conﬁrm a putative role of
ROS in the clinical presentation of mtDNA-related disorders.
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